Safety of biologics for psoriasis patients during the COVID-19 pandemic: the experience from Wuhan, China.
作者信息
Zhao Liang, Du Hongyao, Alamgir Mahin, Yang Jing, Miao Xiaoping, Jiang Biling, Xia Yuting, Lou Yuchen, Wang Yujue, Shen Chen, Zhu Jinjin, Chung Wen-Hung, Li Yan, Tao Juan
机构信息
Department of Dermatology, Affiliated Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, Hubei Engineering Research Center for Skin Repair and Theranostics, Wuhan, China.
Department of Dermatology, Rutgers RWJMS, New Jersey.
出版信息
Eur J Dermatol. 2020 Dec 1;30(6):738-740. doi: 10.1684/ejd.2020.3908.
Abstract
摘要
相似文献
1
Safety of biologics for psoriasis patients during the COVID-19 pandemic: the experience from Wuhan, China.新冠疫情期间生物制剂治疗银屑病患者的安全性：来自中国武汉的经验
Eur J Dermatol. 2020 Dec 1;30(6):738-740. doi: 10.1684/ejd.2020.3908.
2
Compliance, safety concerns and anxiety in patients treated with biologics for psoriasis during the COVID-19 pandemic national lockdown: a multicenter study in the Czech Republic.新冠疫情全国封锁期间接受生物制剂治疗的银屑病患者的依从性、安全担忧及焦虑：捷克共和国的一项多中心研究
J Eur Acad Dermatol Venereol. 2020 Nov;34(11):e682-e684. doi: 10.1111/jdv.16771. Epub 2020 Jul 9.
3
Biologic drugs during COVID-19 outbreak.2019冠状病毒病疫情期间的生物药物
Int J Dermatol. 2020 Oct;59(10):1293. doi: 10.1111/ijd.15088. Epub 2020 Aug 6.
4
Treatment discontinuation and rate of disease transmission in psoriasis patients receiving biologic therapy during the COVID-19 pandemic: A Canadian multicenter retrospective study.2019年冠状病毒病大流行期间接受生物治疗的银屑病患者的治疗中断情况及疾病传播率：一项加拿大多中心回顾性研究
J Am Acad Dermatol. 2020 Oct;83(4):1212-1214. doi: 10.1016/j.jaad.2020.07.021. Epub 2020 Jul 15.
5
Should biologics for psoriasis be interrupted in the era of COVID-19?在新冠疫情时代，银屑病生物制剂是否应中断使用？
J Am Acad Dermatol. 2020 May;82(5):1217-1218. doi: 10.1016/j.jaad.2020.03.031. Epub 2020 Mar 19.
6
COVID, Biologics, and Psoriasis Therapy.新冠病毒、生物制剂与银屑病治疗
J Am Acad Dermatol. 2020 Dec;83(6):1577-1578. doi: 10.1016/j.jaad.2020.09.005. Epub 2020 Sep 10.
7
Biologics increase the risk of SARS-CoV-2 infection and hospitalization, but not ICU admission and death: Real-life data from a large cohort during red-zone declaration.生物制剂增加了感染 SARS-CoV-2 和住院的风险，但不会增加 ICU 收治和死亡的风险：在红色区域宣布期间来自大型队列的真实数据。
Dermatol Ther. 2020 Sep;33(5):e13475. doi: 10.1111/dth.13475. Epub 2020 May 19.
8
A multicenter study on effectiveness and safety of risankizumab in psoriasis: an Italian 16-week real-life experience during the COVID-19 pandemic.司库奇尤单抗治疗银屑病有效性和安全性的多中心研究：意大利在新冠疫情期间的16周真实世界经验
J Eur Acad Dermatol Venereol. 2021 Mar;35(3):e169-e170. doi: 10.1111/jdv.17003. Epub 2020 Nov 8.
9
Use of biologics during the COVID-19 pandemic: lessons learned from psoriasis.2019冠状病毒病大流行期间生物制剂的使用：从银屑病中吸取的经验教训。
Expert Opin Biol Ther. 2022 Dec;22(12):1521-1529. doi: 10.1080/14712598.2022.2110467. Epub 2022 Aug 8.
10
Surveillance of psoriatic patients on biologic treatment during the COVID-19 pandemic: A single-center experience.COVID-19 大流行期间生物治疗的银屑病患者监测：单中心经验。
Dermatol Ther. 2021 Jan;34(1):e14700. doi: 10.1111/dth.14700. Epub 2020 Dec 28.
引用本文的文献
1
Biologics for Psoriasis During the COVID-19 Pandemic.新冠疫情期间用于治疗银屑病的生物制剂
Front Med (Lausanne). 2021 Dec 6;8:759568. doi: 10.3389/fmed.2021.759568. eCollection 2021.
2
Clinical Dermatology and COVID-19 Pandemic: Narrative Review.临床皮肤病学与新冠疫情：叙述性综述
Indian J Dermatol. 2021 May-Jun;66(3):246-255. doi: 10.4103/ijd.ijd_463_21.
本文引用的文献
1
Risk of hospitalization and death from COVID-19 infection in patients with chronic plaque psoriasis receiving a biologic treatment and renal transplant recipients in maintenance immunosuppressive treatment.接受生物治疗的慢性斑块状银屑病患者以及接受维持性免疫抑制治疗的肾移植受者感染新型冠状病毒肺炎（COVID-19）后住院和死亡的风险。
J Am Acad Dermatol. 2020 Jul;83(1):285-287. doi: 10.1016/j.jaad.2020.04.085. Epub 2020 Apr 21.
2
Should biologics for psoriasis be interrupted in the era of COVID-19?在新冠疫情时代，银屑病生物制剂是否应中断使用？
J Am Acad Dermatol. 2020 May;82(5):1217-1218. doi: 10.1016/j.jaad.2020.03.031. Epub 2020 Mar 19.
3
Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.中国武汉成人 COVID-19 住院患者的临床病程和死亡危险因素：一项回顾性队列研究。
Lancet. 2020 Mar 28;395(10229):1054-1062. doi: 10.1016/S0140-6736(20)30566-3. Epub 2020 Mar 11.
4
Risk of Serious Infection in Patients Receiving Systemic Medications for the Treatment of Psoriasis.接受全身性药物治疗银屑病的患者发生严重感染的风险
JAMA Dermatol. 2019 Oct 1;155(10):1142-1152. doi: 10.1001/jamadermatol.2019.1121.
5
Discovery of the IL-23/IL-17 Signaling Pathway and the Treatment of Psoriasis.IL-23/IL-17 信号通路的发现与银屑病的治疗。
J Immunol. 2018 Sep 15;201(6):1605-1613. doi: 10.4049/jimmunol.1800013.
6
Psoriasis pathogenesis and the development of novel targeted immune therapies.银屑病的发病机制与新型靶向免疫疗法的发展
J Allergy Clin Immunol. 2017 Sep;140(3):645-653. doi: 10.1016/j.jaci.2017.07.004.
7
Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis.类风湿关节炎、银屑病关节炎和强直性脊柱炎中使用抗TNF药物的感染风险：一项系统评价和荟萃分析。
Expert Opin Drug Saf. 2016 Dec;15(sup1):11-34. doi: 10.1080/14740338.2016.1240783.
8
BMI, leisure-time physical activity, and physical fitness in adults in China: results from a series of national surveys, 2000-14.中国成年人的 BMI、闲暇时间体力活动和体质：来自 2000-2014 年一系列全国性调查的结果。
Lancet Diabetes Endocrinol. 2016 Jun;4(6):487-97. doi: 10.1016/S2213-8587(16)00081-4. Epub 2016 Apr 28.
Zotero 插件